Rezolute, Inc. (RZLT) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Redwood City, CA, 美国. 现任CEO为 Nevan Charles Elam.
RZLT 拥有 IPO日期为 2013-01-14, 64 名全职员工, 在 NASDAQ Capital Marke, 市值为 $343.55M.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
